Stately Bio

Executive Summary

Stately Bio is a San Diego-based biotechnology company founded in 2021 that is developing next-generation regenerative medicines. The company's core asset is a proprietary machine learning platform that analyzes live-cell, label-free imaging to measure cell identity, behavior, and maturation. This platform serves both as a discovery engine for internal cell therapy programs and as a tool for external partnerships, positioning Stately Bio at the intersection of AI and regenerative medicine. By leveraging real-time cellular insights, the company aims to overcome key challenges in cell therapy development, such as heterogeneity and potency characterization.

Upcoming Catalysts (preview)

• Q3 2026Announcement of major pharma partnership40% success
• Q4 2026Release of preclinical proof-of-concept data for lead program60% success
• Q2 2026Series A or B fundraising round70% success